Biopharma
OrganizationRelationship Network
Event Timeline
| Connected Entity | Relationship Type |
Strength
(mentions)
|
Documents | Actions |
|---|---|---|---|---|
|
organization
NLV-III
|
Financial |
5
|
1 |
| Date | Event Type | Description | Location | Actions |
|---|---|---|---|---|
| 2011-11-01 | N/A | Synageva BioPharma reverse merger to become public | N/A | View |
HOUSE_OVERSIGHT_024045.jpg
This document is a confidential investment report page (marked House Oversight) detailing the track record of New Leaf Ventures (NLV) in the biopharmaceutical sector. It highlights their investment strategy, networking capabilities, and specific performance metrics (multiples on invested capital) for various portfolio companies across funds NLV-I, NLV-II, and Sprout Funds. The text lists specific exits and IPOs occurring between 2011 and 2013.
HOUSE_OVERSIGHT_024043.jpg
This document is page 32 of a confidential investment memorandum (Control Number 257) produced for the House Oversight Committee. It outlines the investment strategy for 'NLV-III' (New Leaf Ventures III), focusing on biopharmaceutical companies with novel products or platforms. The text highlights past successes of the fund managers, listing exit multiples for companies such as Array BioPharma, Pearl Therapeutics, and Epizyme.
HOUSE_OVERSIGHT_024024.jpg
This document (page 13, Control Number 257) contains professional biographies for James Niedel and Liam Ratcliffe, executives at New Leaf Venture Partners. It details their educational backgrounds, board memberships, and extensive history in the pharmaceutical industry (GSK and Pfizer respectively), including specific successful drug developments and corporate acquisitions. The document is marked confidential and bears a House Oversight file stamp.
HOUSE_OVERSIGHT_024835.jpg
This document is page 19 of a Cowen 'Collaborative Insights' report dated February 25, 2019. It details the industry landscape for synthetic biology cannabinoid production, listing specific companies such as Ginkgo Bioworks and Amyris with brief descriptions of their technologies. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was part of a document production for a congressional investigation, though no direct mention of Jeffrey Epstein appears on this specific page.
HOUSE_OVERSIGHT_024761.jpg
This document is Page 125 of a financial report produced by Ackrell Capital, LLC, titled 'Chapter VII Capital Markets for Cannabis Companies.' It contains a data table listing 'Over The Counter' cannabis stocks with market values greater than $25 million as of November 30, 2017. The table provides financial metrics such as stock price, market value, enterprise value, and revenue for numerous entities. The document bears the Bates stamp 'HOUSE_OVERSIGHT_024761', indicating it was part of a document production to the House Oversight Committee, likely related to investigations into financial records.
HOUSE_OVERSIGHT_024100.jpg
This document is a confidential financial appendix (Appendix 1) labeled 'Listing of Investments by Fund' for New Leaf Ventures II, L.P., dated March 31, 2014. It details the financial performance of numerous healthcare, therapeutic, and diagnostic companies in the fund's portfolio, split into realized/partially realized and unrealized investments. The document bears a House Oversight Committee stamp and a confidential control number, indicating it is part of a congressional investigation.
HOUSE_OVERSIGHT_024041.jpg
This document is a page from a confidential financial report or presentation, numbered page 30, bearing a House Oversight Bates stamp. It analyzes 'Biopharma IPO Trends' from 2004 to Q1 2014, showing a significant spike in capital raised and number of IPOs in 2013 and early 2014. The text attributes this growth to the JOBS Act and 'testing the waters meetings,' suggesting a strong opportunity for investors in the healthcare technology sector.
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein entity